docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2024-23-2-27-32docru-30Research ArticleОБЗОРЫREVIEWSАнгиогенные и антиангиогенные факторы в генезе аномалий плацентацииAngiogenic and Antiangiogenic Factors in the Genesis of Placental Abnormalitieshttps://orcid.org/0000-0002-7230-3057ПоникароваН. Ю.PonikarovaN. Yu.

Поникарова Наталия Юрьевна — аспирант кафедры акушерства и гинекологии с клиникой Института медицинского образования 

197341, г. Санкт-Петербург, ул. Аккуратова, д. 2. 

2, Akkuratov Str., Saint Petersburg, 197341.

Ponikarova.Natalia12@yandex.ruhttps://orcid.org/0000-0001-7800-5563АрутюнянА. Ф.ArutiunianA. F.

Арутюнян Арутюн Феликсович — д. м. н., доцент кафедры акушерства и гинекологии с клиникой Института медицинского образования; врач акушер-гинеколог,

195271, Россия, г. Санкт-Петербург, пр-т Мечникова, д. 27. 

2, Akkuratov Str., Saint Petersburg, 197341;

27, Mechnikov Ave., Saint Petersburg, 195271.

h.harutyunyan76@mail.ruhttps://orcid.org/0000-0002-3233-8239ШелеповаЕ. С.ShelepovaE. S.

Шелепова Екатерина Сергеевна — к. м. н., ассистент кафедры акушерства и гинекологии с клиникой Института медицинского образования, врач акушер-гинеколог

197341, г. Санкт-Петербург, ул. Аккуратова, д. 2. 

2, Akkuratov Str., Saint Petersburg, 197341.

shelepova@almazovcentre.ruГодзоеваА. О.GodzoevaA. O.

Годзоева Алина Олеговна  — к. м. н., ассистент кафедры акушерства и гинекологии Института медицинского образования

197341, г. Санкт-Петербург, ул. Аккуратова, д. 2.

2, Akkuratov Str., Saint Petersburg, 197341.

https://orcid.org/0009-0004-5529-770XМаркинаВ. А.MarkinaV. A.

Маркина Валентина Александровна — клинический ординатор кафедры акушерства и гинекологии с клиникой Института медицинского образования,

197341, г. Санкт-Петербург, ул. Аккуратова, д. 2. stulovav.MTL@mail.ru

2, Akkuratov Str., Saint Petersburg, 197341.

stulovav.MTL@mail.ruФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Министерства здравоохранения Российской Федерации; ЧУЗ «Клиническая больница "РЖД-Медицина" города Санкт-Петербурга»РоссияAlmazov National Medical Research Centre; Clinical Hospital “RZD-Medicine” of Saint-PetersburgRussian Federation202413022025232ГИНЕКОЛОГИЯ2732Copyright © Поникарова Н.Ю., Арутюнян А.Ф., Шелепова Е.С., Годзоева А.О., Маркина В.А., 20252025Поникарова Н.Ю., Арутюнян А.Ф., Шелепова Е.С., Годзоева А.О., Маркина В.А.Ponikarova N.Y., Arutiunian A.F., Shelepova E.S., Godzoeva A.O., Markina V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/30Цель обзора

Цель обзора. Оценить роль плацентарного фактора роста (placenta growth factor, PlGF), васкуло-эндотелиального фактора роста (vascular endothelial growth factor, VEGF), растворимой fms-подобной тирозинкиназы 1 (soluble fms-like tyrosine kinase-1, sFlt-1) в патогенезе плацентарной адгезивно-инвазивной патологии (ПАИП).

Основные положения

Основные положения. sFlt-1 является ингибитором ангиогенного действия PlGF и VEGF. Ее концентрация в сыворотке крови пациенток с ПАИП была значимо ниже, чем у женщин с физиологической беременностью во всех исследованиях, представленных в данном обзоре. Только в двух исследованиях определены пороговые значения для сывороточных маркеров при ПАИП, но, по результатам метаанализа, они сильно различались. Несмотря на известную проангиогенную функцию VEGF и PlGF, значимая корреляция между их уровнями не найдена ни в сыворотке крови методом иммуноферментного анализа, ни в экспрессии на клетках хориона, децидуальной ткани и миометрия при аномальной инвазии плаценты.

Заключение

Заключение. Необходимо дальнейшее изучение роли VEFG, PlGF и sFlt-1 в патогенезе ПАИП для поиска их пороговых уровней в крови и использования в качестве диагностических маркеров.

Aim

Aim. To evaluate the role of placenta growth factor (PlGF), vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in the pathogenesis of placental adherent and invasive pathology (PAIP).

Key points

Key points. sFlt-1 is an inhibitor of the angiogenic action of PLGF and VEGF.

The concentration of sFlt-1 in the blood serum of patients with PAIP was significantly lower than in women with physiological pregnancy in all the studies presented in this review. Only two studies have determined thresholds for serum markers for PAIP, but according to the results of the meta-analysis, they had large differences. Despite the known proangiogenic function of VEGF and PlGF, a significant correlation between their levels was not found either in serum by enzyme immunoassay or in expression on chorionic cells, decidual tissue and myometrium in abnormal placental invasion.

Conclusion

Conclusion. Further study of the role of VEFG, PlGF and sFlt-1 in the pathogenesis of PAIP is needed to find their threshold levels in the blood and use as a diagnostic markers.

плацентарная адгезивно-инвазивная патологияпредлежание плацентываскуло-эндотелиальный фактор ростаплацентарный фактор ростарастворимая fms-подобная тирозинкиназа 1рецепторы к васкуло-эндотелиальному фактору роста 1 и 2placental adherent and invasive pathologyplacenta previavascular endothelial growth factorplacenta growth factorsoluble fms-like tyrosine kinase-1vascular endothelial growth factor receptors-l and -2ReferencesWu S., Kocherginsky M., Hibbard J.U. Abnormal placentation: twenty-year analysis. Am. J. Obstet. Gynecol. 2005;192(5): 1458–61. DOI: 10.1016/j.ajog.2004.12.074Wu S., Kocherginsky M., Hibbard J.U. Abnormal placentation: twenty-year analysis. Am. J. Obstet. Gynecol. 2005;192(5): 1458–61. DOI: 10.1016/j.ajog.2004.12.074Mogos M.F., Salemi J.L., Ashley M., Whiteman V.E. et al. Recent trends in placenta accreta in the United States and its impact on maternal–fetal morbidity and healthcare-associated costs, 1998– 2011. J. Matern. Fetal Neonatal Med. 2016;29(7):1077–82. DOI: 10.3109/14767058.2015.1034103Mogos M.F., Salemi J.L., Ashley M., Whiteman V.E. et al. Recent trends in placenta accreta in the United States and its impact on maternal–fetal morbidity and healthcare-associated costs, 1998– 2011. J. Matern. Fetal Neonatal Med. 2016;29(7):1077–82. DOI: 10.3109/14767058.2015.1034103American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta accreta spectrum. Obstet. Gynecol. 2018;132(6):e259–75. DOI: 10.1097/AOG.0000000000002983American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta accreta spectrum. Obstet. Gynecol. 2018;132(6):e259–75. DOI: 10.1097/AOG.0000000000002983Hong S., Le Y., Lio K.U., Zhang T. et al. Performance comparison of ultrasonography and magnetic resonance imaging in their diagnostic accuracy of placenta accreta spectrum disorders: a systematic review and meta-analysis. Insights Imaging. 2022;13(1):50. DOI: 10.1186/s13244-022-01192-wHong S., Le Y., Lio K.U., Zhang T. et al. Performance comparison of ultrasonography and magnetic resonance imaging in their diagnostic accuracy of placenta accreta spectrum disorders: a systematic review and meta-analysis. Insights Imaging. 2022;13(1):50. DOI: 10.1186/s13244-022-01192-wBartels H.C., Postle J.D., Downey P., Brennan D.J. Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis. Markers. 2018;2018:1507674. DOI: 10.1155/2018/1507674Bartels H.C., Postle J.D., Downey P., Brennan D.J. Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis. Markers. 2018;2018:1507674. DOI: 10.1155/2018/1507674Pagani G., Cali G., Acharya G., Trisch I.-T. et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 2018;97(1):25–37. DOI: 10.1111/aogs.13238Pagani G., Cali G., Acharya G., Trisch I.-T. et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 2018;97(1):25–37. DOI: 10.1111/aogs.13238Gorczyca M.E., Springer S., Pateisky P., Ott J. et al. Comparison of ultrasound descriptors of abnormally invasive placenta (AIP) over the course of the second and third trimester — is an increase verifiable? J. Clin. Med. 2021;10(21):4960. DOI: 10.3390/jcm10214960Gorczyca M.E., Springer S., Pateisky P., Ott J. et al. Comparison of ultrasound descriptors of abnormally invasive placenta (AIP) over the course of the second and third trimester — is an increase verifiable? J. Clin. Med. 2021;10(21):4960. DOI: 10.3390/jcm10214960Cubo A.M., Villalba Yarza A., Gastaca I., Lapresa-Alcalde M.V. et al. Cesarean hysterectomy in abnormally invasive placenta: the role of prenatal diagnosis. Diseases. 2021;9(3):56. DOI: 10.3390/diseases9030056Cubo A.M., Villalba Yarza A., Gastaca I., Lapresa-Alcalde M.V. et al. Cesarean hysterectomy in abnormally invasive placenta: the role of prenatal diagnosis. Diseases. 2021;9(3):56. DOI: 10.3390/diseases9030056Shainker S.A., Silver R.M., Modest A.M., Hacker M.R. et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am. J. Obstet. Gynecol. 2020;223(3):433.e1–14. DOI: 10.1016/j.ajog.2020.03.019Shainker S.A., Silver R.M., Modest A.M., Hacker M.R. et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am. J. Obstet. Gynecol. 2020;223(3):433.e1–14. DOI: 10.1016/j.ajog.2020.03.019Jauniaux E., Jurkovic D., Hussein A.M., Burton G.J. New insights into the etiopathology of placenta accreta spectrum. Am. J. Obstet. Gynecol. 2022;227(3):384–91. DOI: 10.1016/j.ajog.2022.02.038Jauniaux E., Jurkovic D., Hussein A.M., Burton G.J. New insights into the etiopathology of placenta accreta spectrum. Am. J. Obstet. Gynecol. 2022;227(3):384–91. DOI: 10.1016/j.ajog.2022.02.038Jauniaux E., Hussein A.M., Fox K.A., Collins S.L. New evidence-based diagnostic and management strategies for placenta accreta spectrum disorders. Best Pract. Res. Clin. Obstet. Gynaecol. 2019;61:75–88. DOI: 10.1016/j.bpobgyn.2019.04.006Jauniaux E., Hussein A.M., Fox K.A., Collins S.L. New evidence-based diagnostic and management strategies for placenta accreta spectrum disorders. Best Pract. Res. Clin. Obstet. Gynaecol. 2019;61:75–88. DOI: 10.1016/j.bpobgyn.2019.04.006Kyozuka H., Yamaguchi A., Suzuki D., Fujimori K. et al. Risk factors for placenta accreta spectrum: findings from the Japan environment and Children’s study. BMC Pregnancy Childbirth. 2019;19(1):447. DOI: 10.1186/s12884-019-2608-9Kyozuka H., Yamaguchi A., Suzuki D., Fujimori K. et al. Risk factors for placenta accreta spectrum: findings from the Japan environment and Children’s study. BMC Pregnancy Childbirth. 2019;19(1):447. DOI: 10.1186/s12884-019-2608-9Pollheimer J., Vondra S., Baltayeva J., Beristain A.G. et al. Regulation of placental extravillous trophoblasts by the maternal uterine environment. Front. Immunol. 2018;9:2597. DOI: 10.3389/fimmu.2018.02597Pollheimer J., Vondra S., Baltayeva J., Beristain A.G. et al. Regulation of placental extravillous trophoblasts by the maternal uterine environment. Front. Immunol. 2018;9:2597. DOI: 10.3389/fimmu.2018.02597Chang C.-W., Wakeland A.K., Parast M.M. Trophoblast lineage specification, differentiation and their regulation by oxygen tension. J. Endocrinol. 2018;236(1):R43–56. DOI: 10.1530/JOE-17-0402Chang C.-W., Wakeland A.K., Parast M.M. Trophoblast lineage specification, differentiation and their regulation by oxygen tension. J. Endocrinol. 2018;236(1):R43–56. DOI: 10.1530/JOE-17-0402Oghbaei F., Zarezadeh R., Jafari-Gharabaghlou D., Ranjbar M. et al. Epithelial-mesenchymal transition process during embryo implantation. Cell Tissue Res. 2022;388(1):1–17. DOI: 10.1007/s00441-021-03574-wOghbaei F., Zarezadeh R., Jafari-Gharabaghlou D., Ranjbar M. et al. Epithelial-mesenchymal transition process during embryo implantation. Cell Tissue Res. 2022;388(1):1–17. DOI: 10.1007/s00441-021-03574-wHanna J., Goldman-Wohl D., Hamani Y., Avraham I. et al. Decidual NK cells regulate key developmental processes at the human fetalmaternal interface. Nat. Med. 2006;12(9):1065–74. DOI: 10.1038/nm1452Hanna J., Goldman-Wohl D., Hamani Y., Avraham I. et al. Decidual NK cells regulate key developmental processes at the human fetalmaternal interface. Nat. Med. 2006;12(9):1065–74. DOI: 10.1038/nm1452Fraser R., Zenclussen A.C. Killer timing: the temporal uterine natural killer cell differentiation pathway and implications for female reproductive health. Front. Endocrinol. 2022;13:904744. DOI: 10.3389/fendo.2022.904744Fraser R., Zenclussen A.C. Killer timing: the temporal uterine natural killer cell differentiation pathway and implications for female reproductive health. Front. Endocrinol. 2022;13:904744. DOI: 10.3389/fendo.2022.904744Shibuya M. Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer. Genes Cancer. 2010;1(11):1119–23. DOI: 10.1177/1947601910392987Shibuya M. Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer. Genes Cancer. 2010;1(11):1119–23. DOI: 10.1177/1947601910392987Lecarpentier E., Tsatsaris V. Angiogenic balance (sFlt-1/PlGF) and preeclampsia. Ann. Endocrinol. 2016;77(2):97–100. DOI: 10.1016/j.ando.2016.04.007Lecarpentier E., Tsatsaris V. Angiogenic balance (sFlt-1/PlGF) and preeclampsia. Ann. Endocrinol. 2016;77(2):97–100. DOI: 10.1016/j.ando.2016.04.007Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M. et al. Vascular endothelial growth factor (VEGF) — key factor in normal and pathological angiogenesis. Rom J. Morphol. Embryol. 2018;59(2):455–67.Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M. et al. Vascular endothelial growth factor (VEGF) — key factor in normal and pathological angiogenesis. Rom J. Morphol. Embryol. 2018;59(2):455–67.De Falco S. The discovery of placenta growth factor and its biological activity. Exp. Mol. Med. 2012;44(1):1–9. DOI: 10.3858/emm.2012.44.1.025De Falco S. The discovery of placenta growth factor and its biological activity. Exp. Mol. Med. 2012;44(1):1–9. DOI: 10.3858/emm.2012.44.1.025Zeisler H., Llurba E., Chantraine F., Vatish M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016;374(1):13–22. DOI: 10.1056/NEJMoa1414838Zeisler H., Llurba E., Chantraine F., Vatish M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016;374(1):13–22. DOI: 10.1056/NEJMoa1414838Kendall R.L., Wang G., Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 1996;226(2):324–8. DOI: 10.1006/bbrc.1996.1355Kendall R.L., Wang G., Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 1996;226(2):324–8. DOI: 10.1006/bbrc.1996.1355Yagel S., Cohen S.M., Goldman-Wohl D. An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array. Am. J. Obstet. Gynecol. 2022;226(2S):S963–72. DOI: 10.1016/j.ajog.2020.10.023Yagel S., Cohen S.M., Goldman-Wohl D. An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array. Am. J. Obstet. Gynecol. 2022;226(2S):S963–72. DOI: 10.1016/j.ajog.2020.10.023Faraji A., Akbarzadeh-Jahromi M., Bahrami S., Gharamani S. et al. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum. J. Obstet. Gynaecol. 2022;42(5):900–5. DOI: 10.1080/01443615.2021.1955337Faraji A., Akbarzadeh-Jahromi M., Bahrami S., Gharamani S. et al. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum. J. Obstet. Gynaecol. 2022;42(5):900–5. DOI: 10.1080/01443615.2021.1955337Rodesch F., Simon P., Donner C., Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet. Gynecol. 1992;80(2):283–5.Rodesch F., Simon P., Donner C., Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet. Gynecol. 1992;80(2):283–5.Милованов А.П. Цитотрофобластическая инвазия — важнейший механизм плацентации и прогрессии беременности. Архив патологии. 2019;81(4):5-10. [Milovanov A.P. Cytotrophoblastic invasion is the most important mechanism of placentation and pregnancy progression. Archive of Pathology. 2019;81(4):5–10. (in Russian)]. DOI: 10.17116/patol2019810415Милованов А.П. Цитотрофобластическая инвазия — важнейший механизм плацентации и прогрессии беременности. Архив патологии. 2019;81(4):5-10. [Milovanov A.P. Cytotrophoblastic invasion is the most important mechanism of placentation and pregnancy progression. Archive of Pathology. 2019;81(4):5–10. (in Russian)]. DOI: 10.17116/patol2019810415Uyanıkoğlu H., İncebıyık A., Turp A.B., Çakmak G. et al. Serum angiogenic and anti-angiogenic markers in pregnant women with placenta percreta. Balk. Med. J. 2018;35(1):55–60. DOI: 10.4274/balkanmedj.2016.1890Uyanıkoğlu H., İncebıyık A., Turp A.B., Çakmak G. et al. Serum angiogenic and anti-angiogenic markers in pregnant women with placenta percreta. Balk. Med. J. 2018;35(1):55–60. DOI: 10.4274/balkanmedj.2016.1890Lumbanraja S., Yaznil M.R., Siahaan A.M., Parda B.B.E. Soluble FMS-like tyrosine kinase: role in placenta accreta spectrum disorder. F1000Res. 2021;10:618. DOI: 10.12688/f1000research.54719.3Lumbanraja S., Yaznil M.R., Siahaan A.M., Parda B.B.E. Soluble FMS-like tyrosine kinase: role in placenta accreta spectrum disorder. F1000Res. 2021;10:618. DOI: 10.12688/f1000research.54719.3Jauniaux E., Ayres-de-Campos D., Langhoff-Roos J., Fox K.A. et al. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int. J. Gynaecol. Obstet. 2019;146(1):20–4. DOI: 10.1002/ijgo.12761Jauniaux E., Ayres-de-Campos D., Langhoff-Roos J., Fox K.A. et al. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int. J. Gynaecol. Obstet. 2019;146(1):20–4. DOI: 10.1002/ijgo.12761Zhang F., Gu M., Chen P., Wan S. et al. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio. Placenta. 2022;124:48–54. DOI: 10.1016/j.placenta.2022.05.009Zhang F., Gu M., Chen P., Wan S. et al. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio. Placenta. 2022;124:48–54. DOI: 10.1016/j.placenta.2022.05.009Schwickert A., Chantraine F., Ehrlich L., Henrich W. et al. Maternal serum VEGF predicts abnormally invasive placenta better than NT-proBNP: a multicenter case-control study. Reprod. Sci. 2021;28(2):361–70. DOI: 10.1007/s43032-020-00319-ySchwickert A., Chantraine F., Ehrlich L., Henrich W. et al. Maternal serum VEGF predicts abnormally invasive placenta better than NT-proBNP: a multicenter case-control study. Reprod. Sci. 2021;28(2):361–70. DOI: 10.1007/s43032-020-00319-yWehrum M.J., Buhimschi I.A., Salafia C., Thung S. et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and epithelial-to-mesenchymal transition of the invasive trophoblast. Am. J. Obstet. Gynecol. 2011;204(5):411.e1–11. DOI: 10.1016/j.ajog.2010.12.027Wehrum M.J., Buhimschi I.A., Salafia C., Thung S. et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and epithelial-to-mesenchymal transition of the invasive trophoblast. Am. J. Obstet. Gynecol. 2011;204(5):411.e1–11. DOI: 10.1016/j.ajog.2010.12.027Alessandrini L., Aryananda R., Ariani G., Agustina B. et al. The correlation between serum levels and placental tissue expression of PLGF and sFLT-1 and the FIGO grading of the placenta accreta spectrum disorders. J. Matern. Fetal Neonatal Med. 2023;36(1):2183744. DOI: 10.1080/14767058.2023.2183744Alessandrini L., Aryananda R., Ariani G., Agustina B. et al. The correlation between serum levels and placental tissue expression of PLGF and sFLT-1 and the FIGO grading of the placenta accreta spectrum disorders. J. Matern. Fetal Neonatal Med. 2023;36(1):2183744. DOI: 10.1080/14767058.2023.2183744Duzyj C.M., Buhimschi I.A., Laky C.A., Cozzini G. et al. Extravillous trophoblast invasion in placenta accreta is associated with differential local expression of angiogenic and growth factors: a cross-sectional study. BJOG. 2018;125(11):1441–8. DOI: 10.1111/1471-0528.15176Duzyj C.M., Buhimschi I.A., Laky C.A., Cozzini G. et al. Extravillous trophoblast invasion in placenta accreta is associated with differential local expression of angiogenic and growth factors: a cross-sectional study. BJOG. 2018;125(11):1441–8. DOI: 10.1111/1471-0528.15176Alzoubi O., Maaita W., Madain Z., Alzoubi M. et al. Association between placenta accreta spectrum and third-trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms-like tyrosine kinase-1: a meta-analysis. J. Obstet. Gynaecol. Res. 2022;48(9):2363–76. DOI: 10.1111/jog.15330Alzoubi O., Maaita W., Madain Z., Alzoubi M. et al. Association between placenta accreta spectrum and third-trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms-like tyrosine kinase-1: a meta-analysis. J. Obstet. Gynaecol. Res. 2022;48(9):2363–76. DOI: 10.1111/jog.15330Zhou B., Hou J., Fu J., Kan C. [Value of color Doppler ultrasound combined with serological markers in diagnosis of placental implantation]. Int. J. Lab. Med. 2020;41(11):1326–8+32.Zhou B., Hou J., Fu J., Kan C. [Value of color Doppler ultrasound combined with serological markers in diagnosis of placental implantation]. Int. J. Lab. Med. 2020;41(11):1326–8+32.Liu Y., Wang D., Wei J., Wu D. [The value of serum VEGF, PlGF and sFlt-1 levels of pregnant women during the third trimester pregnancy for predicting placenta accreta]. Chin. J. Fam. Plann. 2019;27(11):1548–51.Liu Y., Wang D., Wei J., Wu D. [The value of serum VEGF, PlGF and sFlt-1 levels of pregnant women during the third trimester pregnancy for predicting placenta accreta]. Chin. J. Fam. Plann. 2019;27(11):1548–51.Palm M., Basu S., Larsson A., Wernroth L. et al. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1:PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstet. Gynecol. Scand. 2011;90(11):1244–51. DOI: 10.1111/j.1600-0412.2011.01186.xPalm M., Basu S., Larsson A., Wernroth L. et al. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1:PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstet. Gynecol. Scand. 2011;90(11):1244–51. DOI: 10.1111/j.1600-0412.2011.01186.xVerlohren S., Brennecke S.P., Galindo A., Karumanchi S.A. et al. Clinical interpretation and implementation of the sFlt-1/ PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022;27:42–50. DOI: 10.1016/j.preghy.2021.12.003Verlohren S., Brennecke S.P., Galindo A., Karumanchi S.A. et al. Clinical interpretation and implementation of the sFlt-1/ PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022;27:42–50. DOI: 10.1016/j.preghy.2021.12.003Bednarek-Jędrzejek M., Kwiatkowski S., Ksel-Hryciów J., Tousty P. et al. The sFlt-1/PlGF ratio values within the <38, 38–85 and >85 brackets as compared to perinatal outcomes. J. Perinat. Med. 2019;47(7):732–40. DOI: 10.1515/jpm-2019-0019Bednarek-Jędrzejek M., Kwiatkowski S., Ksel-Hryciów J., Tousty P. et al. The sFlt-1/PlGF ratio values within the <38, 38–85 and >85 brackets as compared to perinatal outcomes. J. Perinat. Med. 2019;47(7):732–40. DOI: 10.1515/jpm-2019-0019

The authors declare that there are no conflicts of interest present.